

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Bee Vectoring Technologies International Inc. (the "Issuer").

Trading Symbol: BEE

Number of Outstanding Listed Securities: 112,755,580 common shares were issued and outstanding as of February 28, 2021

Date: March 4, 2021 (for the month of February 2021)

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer, an agriculture technology company, is a market disruptor with a significant global market opportunity in the \$240 billion crop protection and fertilizer market. The Issuer has pioneered a natural precision agriculture system that replaces chemical pesticides and wasteful plant protection product spray applications by delivering biological pesticide alternatives to crops using commercially grown bees. The Issuer's award-winning technology, precision vectoring, is completely harmless to bees and allows minute amounts of naturally-derived pesticides (called biologicals) to be delivered directly to blooms, providing improved crop protection and yield results than traditional chemical pesticides - and improving the health of the soil, the microbiome and the environment. Currently, the Issuer has over 65 granted patents, over 35 patents pending in all major agricultural countries worldwide, and has US EPA registration of its VECTORITE™ with CR-7 (EPA Registration No. 90641-2) for sale as a registered biological fungicide for use on the labelled crops.

2. Provide a general overview and discussion of the activities of management.

During the month of February 2021, management's principal activities consisted of:

- announcing that the Issuer has been issued a commercial license from the California Department of Pesticide Regulation ("CDPR") on its proprietary Vectorite with CR-7 biological fungicide following completion of the CDPR approval review process last month.
- closing a non-brokered private placement of 10,077,500 units ("Units") for gross proceeds of \$3,224,800 in two tranches (the "Private Placement"). Each Unit is comprised of one common share and one share purchase warrant ("Warrant"), each Warrant entitling the holder to acquire one additional common share of the Issuer. Finders warrants of 608,036 were issued to certain finders in connection with the Private Placement;
- announcing that the Issuer will be hosting an Investor Webinar conference to provide a business update and outline the Issuer's progress over the last quarter;
- announcing the first grower trials in berry crops in California;
- the preparation of the Issuer's first quarter interim financial statements and MD&A for the quarter ended December 31, 2020; and
- attending to general administration matters.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

During the month of February, 2021, the Issuer was issued a commercial license from the CDPR on its biological fungicide following completion of the CDPR approval review process in the preceding month, which allows the Issuer's product to be available for sale in California.

The Issuer also announced its first grower trials in berry crops in California. Eight commercial-scale grower trials have already been confirmed, including with two of the world's largest berry companies and their growers. The trials will be conducted on blueberries, caneberries (blackberries and raspberries) and strawberries in the three main growing regions in the state for berries.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

There were no products or services discontinued during the month of February 2021.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

There were no new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements during the month of February 2021.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

There were no contracts or agreements between the Issuer, the Issuer's affiliates or third parties that terminated or expired and there weren't any previously announced financing arrangements that terminated during the month of February 2021.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

There were no acquisitions or dispositions of the Issuer's assets during the preceding month of January 2021.

8. Describe the acquisition of new customers or loss of customers.

There were no acquisitions of new customers or loss of customers during the month of February 2021.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

There were no new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks during the month of February 2021.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

There were no employee hirings, terminations or lay-offs during the month of February 2021.

11. Report on any labour disputes and resolutions of those disputes if applicable.

There were no labour disputes during the month of February 2021.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

There were no legal proceedings to which the Issuer became party to during the month of February 2021.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

There was no indebtedness incurred or repaid by the Issuer during the month of February 2021.

14. Provide details of any securities issued and options or warrants granted.

During the month of February 2021, the following securities were issued:

Security	Number Issued	Details of Issuance	Use of Proceeds
Units ⁽¹⁾	10,007,500	Non-brokered private placement of Units	Proceeds received from the private placement will be used for the Issuer's ongoing growth strategy in the agricultural space, continued research and development and general working capital purposes.
Warrants ⁽²⁾	608,036	Finder's fees payable on non-brokered private placement of Units	Proceeds received from the exercise of Warrants are used for working capital.
Common Shares	1,690,000	Exercise of Warrants	Proceeds received from the exercise of Warrants are used for working capital.
Common Shares	35,500	Conversion of RSU into Common Shares	Proceeds received from the exercise of Stock Options are used for working capital.
Stock Options	155,000	Issuance of Stock Options	N/A

(1) Each Unit is comprised of one Common Share and one Warrant; each Warrant is exercisable for a period of two years from grant to acquire one additional Common share per Warrant at a price of \$0.525 per Common Share.

(2) Each Warrant is exercisable to acquire one additional Common Share for a period of two years from grant at a price of \$0.425 per Common Share.

15. Provide details of any loans to or by Related Persons.

There were no loans to or by Related Persons of the Issuer during the month of February 2021.

16. Provide details of any changes in directors, officers or committee members.

There were no changes in directors, officers or committee members of the Issuer during the month of February 2021.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are detailed in the Issuer's MD&A for the year ended December 31, 2021 dated as of March 1, 2021

under the headings “FINANCIAL INSTRUMENTS”, OTHER RISKS AND UNCERTAINTIES” and “RISKS AND UNCERTAINTIES”. The MD&A is available on the Issuer’s SEDAR profile at www.sedar.com.

In addition to the trends and risks detailed in the MD&A, COVID-19 is likely to impact the Issuer:

COVID-19

The outbreak of the corona virus pandemic has impacted the Issuer’s plans and activities. The Issuer may face disruption to operations, supply chain delays, travel and trade restrictions and impact on economic activity in affected countries or regions can be expected and can be difficult to quantify. Such pandemics or diseases represent a serious threat to maintaining a skilled workforce industry and could be a major health-care challenge for the Issuer. There can be no assurance that the Issuer’s personnel will not be impacted by these pandemic diseases and ultimately that the Issuer would see its workforce productivity reduced or incur increased medical costs/insurance premiums as a result of these health risks. In addition, the COVID-19 pandemic has created a dramatic slowdown in the global economy. The duration of the COVID-19 outbreak and the resultant travel restrictions, social distancing, Government response actions, business closures and business disruptions, can all have an impact on the Issuer’s operations and access to capital. There can be no assurance that the Issuer will not be impacted by adverse consequences that may be brought about by the COVID-19 pandemic on global financial markets may reduce resource prices, share prices and financial liquidity and thereby that may severely limit the financing capital available.

[The remainder of this page is left intentionally blank.]

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated March 4, 2021.

Ashish Malik
Name of Director or Senior
Officer

"Ashish Malik"
Signature

President & CEO
Official Capacity

Issuer Details	For Month End	Date of Report
Name of Issuer		YYYY/MM/D
Bee Vectoring Technologies International Inc.	February 2021	2021/03/04
Issuer Address		
4160 Sladeview Crescent, #7		
City/Province/Postal Code	Issuer Fax No.	Issuer Telephone No.
Mississauga, ON L5L 0A1	(604) 687-3141	(604) 687-2038
Contact Name	Contact Position	Contact Telephone No.
Ashish Malik	President & CEO	(604) 687-2038
Contact Email Address	Web Site Address	
amalik@beevt.com	http://www.beevt.com/	